Clearpoint Neuro Inc (CLPT) - Total Liabilities

Latest as of March 2026: $74.58 Million USD

Based on the latest financial reports, Clearpoint Neuro Inc (CLPT) has total liabilities worth $74.58 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Clearpoint Neuro Inc (CLPT) net asset momentum to track the company's year-over-year net asset growth rate.

Clearpoint Neuro Inc - Total Liabilities Trend (2011–2025)

This chart illustrates how Clearpoint Neuro Inc's total liabilities have evolved over time, based on quarterly financial data.

Clearpoint Neuro Inc Competitors by Total Liabilities

The table below lists competitors of Clearpoint Neuro Inc ranked by their total liabilities.

Company Country Total Liabilities
Shenzhen Zqgame
SHE:300052
China CN¥366.57 Million
Jiangxi Synergy Pharmaceutical Co Ltd
SHE:300636
China CN¥927.61 Million
Braskem S.A.
SA:BRKM3
Brazil R$90.56 Billion
Hunan Creator Information Technologies Co Ltd Class A
SHE:300730
China CN¥397.39 Million
Lion Travel Service Co Ltd
TW:2731
Taiwan NT$8.20 Billion
Dnake Xiamen Intelligent Technology
SHE:300884
China CN¥473.61 Million
FLAT GLASS GROUP H YC-25
F:72T
Germany €19.77 Billion
Guolin Environmental Tech Co Ltd
SHE:300786
China CN¥658.63 Million

Liability Composition Analysis (2011–2025)

This chart breaks down Clearpoint Neuro Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Clearpoint Neuro Inc (CLPT) total market value.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 5.79 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 3.96 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.80 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Clearpoint Neuro Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Clearpoint Neuro Inc (2011–2025)

The table below shows the annual total liabilities of Clearpoint Neuro Inc from 2011 to 2025.

Year Total Liabilities Change
2025-12-31 $69.73 Million +405.27%
2024-12-31 $13.80 Million -35.78%
2023-12-31 $21.49 Million +15.51%
2022-12-31 $18.60 Million +10.77%
2021-12-31 $16.79 Million -38.12%
2020-12-31 $27.14 Million +269.72%
2019-12-31 $7.34 Million +15.68%
2018-12-31 $6.35 Million -21.35%
2017-12-31 $8.07 Million -1.08%
2016-12-31 $8.16 Million -32.50%
2015-12-31 $12.08 Million -10.40%
2014-12-31 $13.49 Million -8.30%
2013-12-31 $14.71 Million +30.28%
2012-12-31 $11.29 Million -54.62%
2011-12-31 $24.87 Million --

About Clearpoint Neuro Inc

NASDAQ:CLPT USA Medical Devices
Market Cap
$426.15 Million
Market Cap Rank
#13077 Global
#3173 in USA
Share Price
$14.21
Change (1 day)
+6.12%
52-Week Range
$8.66 - $29.60
All Time High
$29.60
About

ClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in the United States. The company offers ClearPoint systems, such as ClearPoint hardware, which includes head fixation frame, computer workstation, and in-room monitor; and ClearPoint disposables, which … Read more